NDAINHALATIONPOWDER, METERED
Approved
Mar 2019
Lifecycle
LOE Approaching
Competitive Pressure
15/100
Clinical Trials
2
Data completeness
7/8 — Comprehensive
DUAKLIR PRESSAIR (aclidinium bromide and formoterol fumarate) by Azurity is bronchodilators: aclidinium a long-acting muscarinic antagonist (also known as an anticholinergic) and formoterol a long-acting beta 2 -adrenergic agonist. Approved for chronic obstructive pulmonary disease, copd, asthma. First approved in 2019.
Drug data last refreshed 13h ago · AI intelligence enriched 2mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
DUAKLIR PRESSAIR is a fixed-dose combination inhalation powder containing aclidinium bromide (a long-acting muscarinic antagonist) and formoterol fumarate (a long-acting beta-2 agonist) for the treatment of chronic obstructive pulmonary disease (COPD). The two active components work synergistically through different mechanisms: aclidinium blocks M3 muscarinic receptors to relax airway smooth muscle, while formoterol stimulates beta-2 adrenergic receptors to further promote bronchodilation and inhibit mediator release from mast cells.
$0.049MPart D
LOE ApproachingDeclining
2.5 years to LOEWith LOE approaching in 2.7 years and modest Part D spending of $49K, the brand team is likely consolidating focus on market defense rather than growth initiatives, suggesting smaller sales force and prioritized account management.
Mechanism of Action
bronchodilators: aclidinium a long-acting muscarinic antagonist (also known as an anticholinergic) and formoterol a long-acting beta 2 -adrenergic agonist. Further information regarding these two substances is provided below. The mechanism of action described below for the individual components…
Worked on DUAKLIR PRESSAIR at Azurity? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.